Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight

Summary

DelveInsight market analysis projects significant growth in the hypertrophic cardiomyopathy market driven by emerging targeted disease-modifying therapies, including Lexicon Pharmaceuticals' Sotagliflozin (ZYNQUISTA), alongside improved disease awareness and diagnosis rates.